A team of researchers at Dana-Farber Cancer Institute developed a new compound that appears to trigger cancer cell suicide.
Five months after Takeda announced it was formally integrating its R&D efforts in San Francisco and San Diego into a single entity, the Japanese pharma company dropped the news that it will now shutter its Bay Area ops and move its most essential staffers and technology down south into an expanded "center of excellence."
There's a new strategy on tap to defeat cancer, and it's all about genes. Scientists at Penn State believe that they can suppress a specific gene's enzyme-related activity in a way to reactivate a genetic response that causes tumors to kill themselves.
The avalanche of ASCO abstracts last night triggered a flurry of news reports about the most notable new data on experimental therapies to be revealed ahead of next month's big meeting in Chicago.
Scientists at the Cancer Institute of New Jersey and the Institute for Advanced Study have identified a class of compounds--known as thiosemicarbazones--that appears in early testing to correct p53's mutation in mice. Treated with the compounds, tumors either stopped growing so quickly or shrank.
Later this week the cancer drug research crowd will examine a tsunami of abstracts filed ahead of the ASCO meeting in early June in the hopes of finding a few gems.
The Thousand Oaks, CA-base drugmaker is one of 30 organizations on the docket today for the FDA's informal stakeholder meeting to discuss regulation of biosimilars.
Cancer is bad enough, but anxiety could make the disease even worse as it progresses.
Scientists believe they've identified a potential new treatment, dubbed Lenaldekar (LDK) which defeated T-cell acute lympoblastic leukemia in genetically modified zebrafish.
Bayer has racked up a fresh set of preliminary late-stage data that will bolster its plans to market regorafenib for a range of cancers.